Table 3.
Adverse events with dalbavacin Phase III clinical trial of 854 patients (42)
| Percentage of patients | ||
|---|---|---|
| Adverse event | Dalbavancin arm (n = 571) | Linezolid arm (n = 283) |
| Any event | 25.4 | 32.2 |
| Nausea | 3.2 | 5.3 |
| Diarrhoea | 2.5 | 5.7 |
| Elevated blood lactate dehydrogenase level | 1.9 | 1.8 |
| Headache | 1.9 | 1.8 |
| Elevated –γ glutamyltransferase level | 1.9 | 1.4 |
| Vomiting | 1.9 | 1.1 |
| Rash | 1.8 | 1.8 |
| Abnormal liver function test results | 1.6 | 1.1 |
| Elevated alanine aminotransferase level | 1.2 | 1.8 |
| Fungal vaginosis | 0.9 | 1.8 |
| Loose stools | 0.4 | 2.1 |
| Thrombocytopenia | 0.2 | 2.5 |